Clinical Trial Goal
To find out:
- The highest dose of UB-VV111 that's safe to give with rapamycin
- If UB-VV111, plus rapamycin, is safe and works well to treat CLL or large B-cell lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have CLL or large B-cell lymphoma that has relapsed or is refractory
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with any of the following:
- Allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Gene therapy
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Rapamycin is a protein kinase inhibitor that is used for immunosuppression.
UB-VV111 is a type of gene therapy that generates CD19 CAR T-cells in the body.
You’ll get:
UB-VV111 is a type of gene therapy that generates CD19 CAR T-cells in the body.
You’ll get:
- Rapamycin – The dose you'll get depends on when you started the trial and how safe it has been
- UB-VV111 – The dose you'll get depends on when you started the trial and how safe it has been
You’ll have scans to see how well treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved UB-VV111.
Contacts
Jacob Garcia, MD, 425-873-8331, jacob.garcia@umoja-biopharma.com
Christine Dehner, christine.dehner@umoja-biopharma.com
Locations
Sponsors
lead: Umoja Biopharma
